化合物CT52923 T60226
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 9
- 1
Product IntroductionBioactivity英文名: CT52923描述: CT52923 is a selective, orally active antagonist of platelet-derived growt
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: CT52923
描述: CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
体外活性: CT52923 inhibits PDGFRs and stem cell factor receptors with IC50 values of 100 to 200 nM. CT52923（0.01-30 μ M； 24 h) blocks smooth muscle cell migration or fibroblast proliferation induced by platelet-derived growth factor, IC50 is 64 and 280 nM respectively [1].
体内活性: CT52923 (oral; 5,15,30 and 50 mg/kg; twice daily) significantly inhibits the formation of neointima after carotid artery injury in rats [1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 60 mg/mL (128.33 mM)
关键字: CT 52923 | CT-52923 | CT52923
相关产品: AG-1478 | Regorafénib N-oxyde (M2) | Ilorasertib | Eupatolide | Axitinib | SU14813 | Regorafenib Hydrochloride | SU4312 | Multi-kinase inhibitor 1 | ON123300
相关库: Anti-Cancer Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Anti-Lung Cancer Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Bioactive Compound Library
Bioactivity
英文名: CT52923
描述: CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
体外活性: CT52923 inhibits PDGFRs and stem cell factor receptors with IC50 values of 100 to 200 nM. CT52923（0.01-30 μ M； 24 h) blocks smooth muscle cell migration or fibroblast proliferation induced by platelet-derived growth factor, IC50 is 64 and 280 nM respectively [1].
体内活性: CT52923 (oral; 5,15,30 and 50 mg/kg; twice daily) significantly inhibits the formation of neointima after carotid artery injury in rats [1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 60 mg/mL (128.33 mM)
关键字: CT 52923 | CT-52923 | CT52923
相关产品: AG-1478 | Regorafénib N-oxyde (M2) | Ilorasertib | Eupatolide | Axitinib | SU14813 | Regorafenib Hydrochloride | SU4312 | Multi-kinase inhibitor 1 | ON123300
相关库: Anti-Cancer Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Anti-Lung Cancer Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Bioactive Compound Library
猜你喜欢
感兴趣产品